SCHEMBL2176885

SCHEMBL2176885

CCCCCNC(=O)N(C)c1cccc(-c2ccc(CC(OCC3CC3)C(=O)OC)cc2)c1

nearest known ligand 0.40

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PLG P00747 13/20 0.40
PRSS1 P07477 13/20 0.40
PRSS2 P07478 13/20 0.40
PRSS3 P35030 13/20 0.40
ITGB3 P05106 2/20 0.36
ITGAV P06756 2/20 0.36
PTGS2 P35354 1/20 0.36
PLAU P00749 1/20 0.36
MMEL1 Q495T6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2176888 1.00 PLG (0.40) PLGPRSS1PRSS2PRSS3ITGB3
SCHEMBL2174985 0.99 PLG (0.42) PLGPRSS1PRSS2PRSS3ITGB3
SCHEMBL2174447 0.93 PLG (0.42) PLGPRSS1PRSS2PRSS3ITGB3
SCHEMBL2174444 0.93 PLG (0.42) PLGPRSS1PRSS2PRSS3ITGB3
SCHEMBL2175784 0.92 PLG (0.43) PLGPRSS1PRSS2PRSS3ITGB3
SCHEMBL2175781 0.92 PLG (0.43) PLGPRSS1PRSS2PRSS3ITGB3
SCHEMBL2174734 0.90 PTGS2 (0.40) PLGPRSS1PRSS2PRSS3ITGB3
SCHEMBL2175536 0.89 PTGS2 (0.40) PLGPRSS1PRSS2PRSS3ITGB3
SCHEMBL2175533 0.89 PTGS2 (0.40) PLGPRSS1PRSS2PRSS3ITGB3
SCHEMBL3943395 0.88 PLG (0.38) PLGPRSS1PRSS2PRSS3ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973063-B2 Methods for activating PPAR gamma-type receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-07-05 US claimed
US-20100035988-A1 Methods for activating PPAR gamma-type receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-02-11 US claimed
US-7626054-B2 Biaromatic compounds which activate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-12-01 US claimed
US-20070112070-A1 Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-05-17 US claimed
US-7973063-B2 Methods for activating PPAR gamma-type receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-07-05 US disclosed
US-20100035988-A1 Methods for activating PPAR gamma-type receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-02-11 US disclosed
US-7626054-B2 Biaromatic compounds which activate PPARγ-type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-12-01 US disclosed
US-20070112070-A1 Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112070-A1 Novel biaromatic compounds which activate PPARy-type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARD, PPARA PLG 967/4885PRSS1 3239/4885PRSS2 3799/4885
US-20100035988-A1 Methods for activating PPAR gamma-type receptors PPARG, PPARA, PPARD PLG 391/4885PRSS1 4084/4885PRSS2 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.